Morgan Stanley Maintains Overweight on BUD Anheuser-Busch InBev Feb 2026

Morgan Stanley on February 18, 2026 maintained an Overweight rating on Anheuser-Busch InBev SA/NV (BUD) and raised its price target to EUR 74 from EUR 66.50. The move is recorded at 11:58 AM and follows AB InBev’s recent Q4 2025 results and guidance. The BUD analyst rating update signals continued confidence from a major sell-side desk while leaving the call at Overweight rather than upgrading outright. Investors should note the new price target and how it ties to valuation and medium-term EPS expectations.

BUD analyst rating: Morgan Stanley maintains Overweight and raises price target

Morgan Stanley maintained Overweight on February 18, 2026 and raised the price target to EUR 74 from EUR 66.50, according to TheFly source. The firm left its positive stance intact while lifting valuation assumptions. This action keeps Morgan Stanley among the more constructive analysts covering BUD.

Price target change and valuation implications for BUD price target

A move from EUR 66.50 to EUR 74 raises implied upside versus current market prices and signals higher medium-term value expectations. The raised price target suggests Morgan Stanley now models stronger margin recovery or higher revenue growth assumptions. For investors, a higher target narrows the gap to the firm’s fair value and can support follow-through buying if fundamentals confirm the thesis.

Earnings context that shaped the BUD analyst rating

AB InBev reported Q4 2025 results and guidance pointing to 4%–8% organic EBITDA growth and margin expansion, which likely influenced Morgan Stanley’s adjustment source. The earnings call highlighted buybacks, EPS growth, and beverage diversification that underpin the maintained Overweight view. Those operational details feed directly into sell-side models and price target moves.

What the maintained rating means for investors and BUD upgrade/downgrade signals

Maintaining Overweight is a reaffirmation rather than an upgrade or downgrade; it signals conviction but not a change in recommendation stance. For investors, this means Morgan Stanley still expects BUD to outperform peers, but the adjustment to the EUR 74 target reflects refinements in assumptions. Traders should treat this as positive confirmation, while long-term holders should weigh the revised valuation against corporate guidance and cash return plans.

Historical analyst coverage and how this fits AB InBev’s trend

Historically, AB InBev has drawn mixed but generally favorable coverage from large global banks, with periodic target revisions tied to commodity costs, pricing, and regional trends. Morgan Stanley’s maintained Overweight continues a pattern of selective optimism from major brokers when AB InBev shows margin improvement. The new price target follows prior upgrades and target raises during recovery phases since 2023.

Meyka Grade, market cap and short-term market signals

Meyka AI rates BUD with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The company’s market cap stands at $153,289,589,739. Meyka AI-powered market analysis shows that maintained positive ratings combined with buyback signals and clear EBITDA guidance can support multiple expansion in the near term.

Final Thoughts

Morgan Stanley’s February 18, 2026 action left its Overweight rating intact while raising the price target to EUR 74, which communicates ongoing confidence without a full recommendation change. The BUD analyst rating update ties directly to Q4 2025 results, margin guidance, and buyback plans. Investors should view the action as a positive validation of AB InBev’s operational path, not a signal of immediate outperformance.

Key takeaways: Morgan Stanley’s maintained Overweight supports a cautious bullish view; the EUR 74 target raises the bar for valuation, and Meyka AI rates BUD with a grade of B+. The grade balances benchmark and sector comparisons, growth metrics, and analyst consensus. These views are informational and not financial advice; investors should cross-check company results, price action, and their risk profile before trading.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.